OBJECTIVES. To assess whether targeted short-term fluconazole prophylaxis reduces late-onset (Ͼ3 days of age) invasive fungal infection (IFI) among very low birth weight infants and extremely low birth weight (ELBW) infants and to assess mortality rates, toxicity, and costs associated with this intervention.
F UNGAL SEPSIS OR other invasive fungal infection (IFI) occurs for 2% to 4% of very low birth weight (VLBW) infants (birth weight [BW] : Ͻ1500 g) and 10% of extremely low BW (ELBW) infants (BW: Ͻ1000 g). [1] [2] [3] [4] Factors associated with late (Ͼ3 days of age) IFI among neonates in at least some multivariate analyses include low gestational age (GA) (GA Ͻ28 weeks, especially Ͻ25 weeks), ELBW, severe illness at birth, duration of antibiotic administration, use of third-generation cephalosporins and carbapenems, central line, umbilical venous catheter in place for Ͼ7 days, mechanical ventilation, intravenous parenteral nutrition for Ͼ5 days, intravenous lipid infusion for Ͼ7 days, fungal colonization, time to full enteral feeding containing breast milk of Ͼ2 weeks, use of histamine receptor subtype 2 antagonists, necrotizing enterocolitis (NEC), bowel perforation, and thrombocytopenia. 1, [3] [4] [5] [6] It is important to note the tremendous variability in risk factors among studies. Empirical therapy pending culture results may be justified if the infant meets specific criteria, because of high attributable mortality rates (21-32%), acute and long-term neurodevelopmental morbidity associated with IFI, and lack of specificity of clinical presentation. 1,2,4-8 A study of a Norwegian national cohort of extremely premature infants 9 showed that late-onset sepsis was associated with high Clinical Risk Index for Infants (CRIB) scores, 10 an umbilical venous catheter in situ for 7 days, and time of achievement of full enteral feeding with human breast milk, with an adjusted relative risk (RR) of 3.7 (95% confidence interval [CI]: 2.0 -6.9) for late-onset sepsis if full enteral feeding (with the infant's own mother's milk or banked breast milk) was not established within the second week of life. Fungal sepsis was observed for all 5 deaths among 19 infants with NEC or perforation in that study. 10 Data from the National Institute of Child Health and Human Development (NICHD) Neonatal Research Network NICUs showed that center differences in Candida IFI rates (ranging from 2.4% to 20.4% among ELBW infants) were at least in part related to a strong association between candidemia among ELBW infants and prolonged antibiotic administration. 11 Prophylaxis of IFI has been proposed for several populations at risk, including neutropenic patients with cancer, patients with HIV, solid-organ transplant recipients, critically ill surgical patients, patients with chronic granulomatous disease, patients with previous invasive mycosis who need additional immunosuppression, and VLBW infants. [12] [13] [14] [15] One medication used commonly for prophylaxis is fluconazole, 1 of several antifungal azoles that inhibit cytochrome P-450-dependent 14␣-lanosterol demethylase (P-55014DM or ERG11) and have high affinity for the fungal enzyme, compared with the mammalian enzyme. [16] [17] [18] A survey showed that 34% of neonatologists in the United States routinely used some kind of antifungal prophylaxis, most often (66%) fluconazole. 19 Crude data obtained from our NICU database (L.M.S.)
showed that the frequency of late IFI (defined as developing among patients surviving after 3 days of life) 11 These data were confirmed in a multivariate analysis that compared our data with those of the Vermont Oxford Neonatal Network for the 3-year period from 2000 to 2002. The adjusted odds ratio (OR) for IFI among VLBW infants (specifically, 501-1500 g), obtained as a standardized ratio (observed/expected), was 2.67 (95% CI: 1.91-3.42). Therefore, for a period of 4 years between 1998 and 2002, we had a frequency of IFI among these infants that was 2 to 4 times greater than expected. In March 2003, evidence-based analysis with the critically appraised topic method included a review of our own data and the Cochrane review by McGuire et al. 14 On the basis of this analysis, all faculty members in the section of neonatology at Weiler Hospital and the quality improvement committee decided to initiate routine fluconazole prophylaxis. The purpose of this article is to report our experience with targeted fluconazole prophylaxis.
METHODS

Inclusion and Exclusion Criteria
We included all inborn infants with GA of Ͻ32 weeks or BW of Ͻ1500 g. Early-onset IFI, defined as a blood culture or spinal tap sample positive for fungus before 72 hours of life, was excluded from the analysis (see below)
Study Epochs
During the first (control) epoch (January 1, 2001, through December 31, 2002 ; n ϭ 206 infants), we did not use fluconazole prophylaxis. During the second (fluconazole) epoch (July 1, 2003, through December 30, 2004 ; n ϭ 178 infants), targeted fluconazole prophylaxis was used for all infants with GA of Ͻ32 weeks or BW of Ͻ1500 g.
Targeted Fluconazole Prophylaxis
We selected targeted fluconazole prophylaxis during periods of antibiotic administration of Ͼ3 consecutive days, thereby targeting high-risk patients while minimizing the duration of exposure to fluconazole. Fluconazole was administered intravenously over 30 minutes at a dose of 3 mg/kg, at intervals ranging between every third day and every day, depending on postmenstrual age. 20 Fluconazole administration was stopped if levels of both transaminases were Ͼ150 IU/L or if the direct bilirubin level was Ͼ5 mg/dL, and the interval of administration was adjusted for patients with renal failure.
Patients with suspected IFI (thrombocytopenia, tracheal yeast colonization, or cutaneous yeast infection associated with clinical deterioration) received a blood culture, urine culture, and spinal tap and received amphotericin (or any appropriate medication for the infection) for 5 days, pending culture results. Those with proven IFI received amphotericin (or any appropriate medication, on the basis of sensitivity, end-organ damage, and response to therapy) for Ն3 weeks.
Outcome Variables
The primary outcome variable was IFI, defined as a blood, cerebrospinal fluid, or urine culture positive for fungus. Evidence for end-organ damage was assessed routinely with cultures as just described, with head and abdomen ultrasound scans for assessment of the possibility of ventriculitis, brain abscess, or renal or hepatosplenic disease, and with echocardiograms and eye examinations for assessment of possible endophthalmitis. 21 Secondary outcomes variables were secondary analysis of IFI, mortality rates, type of fungus, morbidity and specific mortality rates for IFI, toxicity (including maximal direct bilirubin and transaminase levels), cost analysis, and percentage of resistant strains among infected patients during the second epoch. Cost analysis was performed with the following variables: (1) cost of a premixed bag of fluconazole ($14.66), which can be used for a few doses if Ͼ1 infant in the NICU requires treatment at the same time; (2) cost of 1 day of hospitalization in a NICU ($3000); and (3) length of stay (LOS) and morbidity and mortality rates in our study.
Sample Size and Statistical Analyses
Statistical analyses of the primary outcome variable were performed with the intention-to-treat approach (ie, belonging to the fluconazole epoch versus the control epoch, regardless of whether the patient received fluconazole effectively). We used SPSS version 13 software (SPSS, Chicago, IL), 2-tailed tests, and P Ͻ .05 as the criterion for statistical significance. We performed a Cochran-Mantel-Haenszel 2 analysis to assess the effect attributable to epoch, taking into account groups of BW (Ն1000 g versus Ͻ1000 g).
Next, we performed a logistic regression analysis to test whether belonging to the fluconazole epoch reduced the odds of late IFI. In the first model, we entered all factors reported previously (except for fungal colonization, which was not available to us because surveillance fungal cultures were not obtained routinely in our NICU). To assess which variables were significant in our study, we removed, one by one, variables with the highest P values until all variables had P values of Ͻ.05. We checked the adequacy of the model with the HosmerLemeshow goodness-of-fit statistic. We combined NEC and perforation, as well as GA groups of 23 to 24 and 25 to 27 weeks, into a single variable, to avoid collinearity. To test whether changes in infection control could in part explain changes in IFI rates, we used another model that included the numbers of episodes of proven bacterial sepsis (ie, with Ն1 positive blood or cerebrospinal fluid culture) and of clinical sepsis.
Sample size analysis was performed with Sample Power software (SPSS), with the assumption of a baseline (before introduction of fluconazole prophylaxis) IFI rate of 10%. With 2 analysis, a P value of .05, and a power of 0.80, we would need 138 patients in each epoch to detect an 80% reduction in the frequency of outcome (as reported in a systematic review of randomized trials of fluconazole prophylaxis among low BW infants), 14 with 184 patients in each epoch being needed to reach a power of 90%.
Secondary Outcomes
We used 2 analysis (Fisher's exact test or Cochran-Mantel-Haenszel test) for dichotomous variables and Student's t test, analysis of variance, or Mann-Whitney test with exact probability for other variables. For variables skewed to the right for which a logarithmic transformation was either impossible (range included 0) or did not yield a Gaussian distribution, we used both the Mann-Whitney test and 2 analysis. Values are presented as median (with interquartile range [IQR] or range) or mean Ϯ SD.
Protection of Human Subjects
Fluconazole is not approved by the Food and Drug Administration for neonatal use, including prophylaxis of neonatal IFI. Initiation of fluconazole prophylaxis in our NICU was based on an observational quality improvement project and was not undertaken with the goal of obtaining approval of this drug for neonatal use. Therefore, we did not obtain an investigational new drug application. A recent survey showed that approximately one third of the neonatologists in the United States use routine antifungal prophylaxis for ELBW infants. 19 Chart review for the multivariate analysis was conducted with approval from the Montefiore Medical Center institutional review board.
RESULTS
Demographic and Patient Characteristics
There was no significant difference in GA or BW between the 2 epochs (Table 1) . CRIB scores, number of episodes of clinical sepsis and bacterial sepsis, and total duration of antibiotic therapy were lower in the second epoch than in the first epoch, and the frequency of NEC tended to increase during the second epoch. The percent-age of infants with bacterial sepsis was significantly lower during the second epoch than during the first epoch, with a common OR of 0.581 (95% CI: 0.357-0.945; P ϭ .028, Cochran test, adjusting for BW [Ͻ1 kg versus Ն1 kg]).
Primary Outcome Variable
IFI Rates
Late-onset IFI was observed for 15 infants, at a median age of 25 days (range: 7-94 days) ( Tables 2-4 
IFI Versus Published Factors
Logistic regression taking into account all published variables (except for fungal colonization) showed that the 18 (11) (Table 3) .
IFI Versus Infection Control
The numbers of cases of bacterial sepsis and clinical sepsis were entered into and kept in the model (n ϭ 384) while other nonsignificant variables were removed (Table 4). 
Description of IFI
Among the 15 infected infants, 14 had positive blood cultures, 2 had positive urine cultures, 1 had a positive peritoneal culture, and 1 had a positive tracheal culture. All infants had thrombocytopenia but none had ventriculitis, endophthalmitis, endocarditis, or ultrasonographic evidence of fungal infection of the kidney or hepatosplenic abscess. One infant in the control epoch had 2 episodes of IFI with Candida albicans, 1 had C albicans only in the urine, and another 1 had simultaneously Candida parapsilosis in the blood and C albicans in the urine. Strains included C albicans (n ϭ 7; 5 infants plus 1 infant with 2 episodes of IFI and 1 with C albicans in the urine and C parapsilosis in the blood), C parapsilosis (n ϭ 9), and Candida lusitaniae (n ϭ 1) ( Table 2) . Two ELBW infants with IFI died in the control epoch, 1 at day For this logistic regression analysis, the numbers of episodes of clinical sepsis and of bacterial sepsis were entered into the first model shown in Table 3 and were kept in the model while any other variables that did not reach statistical significance were removed progressively.
9 after 2 days of amphotericin treatment (C albicans) and 1 on day 65 after 47 days of amphotericin treatment (C parapsilosis). The mortality rate for ELBW infants with IFI was low (15%) in our study, compared with previous reports (37-40%), presumably because of predominance of C parapsilosis in our study (9 of 15 patients, 60%; 9 of 17 isolates, 53%). The median duration of amphotericin therapy was 29 days (range: 2-54 days). All patients but 1 had received a third-generation cephalosporin, carbapenem, or both before the IFI, and the total duration of antibiotic treatment before IFI was 18.5 days (range: 0 -41 days). 
Cost Analysis
Toxicity and Emergence of Resistance
The frequencies of serum direct bilirubin levels of Ͼ5 mg/dL and of aspartate aminotransferase levels of Ͼ150 IU/L were significantly lower in the fluconazole epoch than in the control epoch (Table 2) . Maximal direct bilirubin and transaminase levels were lower during the second epoch than during the first epoch ( Table 2 ). The minimal inhibitory concentration (MIC) for fluconazole was available for 1 infected patient during the first epoch (C albicans, 0.25 g/mL) and for 2 infected patients during the second epoch (C albicans, 1 g/mL; C lusitaniae, 4.8 g/mL). All strains were sensitive to amphotericin B.
DISCUSSION
Fluconazole is the most commonly (66%) used medication for fungal prophylaxis among ELBW infants. 19 Although other prophylactic strategies have been used (eg, oral administration of antifungal agents such as nystatin, miconazole, or fluconazole), the numbers of subjects assigned randomly were much too small to allow any recommendation. 22 In any case, a strategy based entirely on enteral prophylaxis might have limited use for highrisk ELBW infants, who are the ones with limited or no food intake. 9 The systematic review by McGuire et al 14 showed that continuous fluconazole prophylaxis for 4 to 6 weeks reduces the risk for IFI among VLBW and ELBW infants. The systematic review included 3 single-site, randomized trials, [23] [24] [25] (1) potential risks, such as development of fungal resistance, toxicity of fluconazole, and interference with the metabolism of other medications, and (2) cost. Kicklighter et al 23 assigned randomly 103 VLBW infants, within the first 3 days of life, to receive either intravenously administered (enterally administered when the infant was receiving full enteral feeding) fluconazole (6 mg/kg) or placebo, administered every 72 hours during the first 7 days of life and then every 24 hours until day 28), to assess the effect of fluconazole on fungal colonization. Kaufman et al 24 assigned randomly 100 ELBW infants who were either intubated or had a central venous catheter present in the first 5 days of life to receive either 3 mg/kg fluconazole or placebo every third day for the first 2 weeks, every other day during the third and fourth weeks, and every day during the fifth and sixth weeks. Cabrera et al 25 assigned randomly 11 VLBW infants with fungal colonization to receive either 6 mg/kg fluconazole or placebo, given intravenously until intravenous access was no longer otherwise required. Death before hospital discharge, as reported in 2 of these tri-als, 23, 24 24 showed a significant reduction in fungal sepsis rate. Kaufman et al 27 recently completed another randomized trial, which showed that twice-weekly administration of fluconazole for 6 weeks among high-risk ELBW infants yielded results that were similar to those achieved with the previous schedule; the authors observed no development of resistance to fluconazole among 81 patients during a 24-month period. Two studies with a before/after study design similar to our study, 1 with ELBW infants and 1 with VLBW infants, were published recently. 28, 29 Both studies showed significant efficacy of fluconazole prophylaxis in IFI; 1 showed a significant decrease in mortality rate, whereas the other showed a trend toward an increase in IFI rate among larger, more mature infants not exposed to fluconazole prophylaxis. 28 The OR of IFI associated with the fluconazole epoch in our study was similar to the OR associated with the 4-to 6-week course in randomized, controlled trials reported by McGuire et al 14 (OR: 0.18; 95% CI: 0.06 -0.59). Targeted short-term fluconazole therapy may be as efficacious in reducing the risk of IFI as a 4-to 6-week continuous course but exposes only 51% of all infants and 80% of ELBW infants to fluconazole, for a shorter time. In our study, the median number of doses was 6 among infants of Ͻ1500 g or Ͻ32 weeks who received the medication effectively and the median was 8 among ELBW infants who received fluconazole, compared with 23 or 24 doses in the original studies by Kicklighter et al 23 and Kaufman et al, 24 12 doses in the recent trial by Kaufman et al, 27 25 doses in the study by Healy et al, 28 and 23 doses of 6 mg/kg in the study by Bertini et al. 29 Therefore, targeted short-term fluconazole therapy, by reducing exposure and cost but not efficacy, is an attractive alternative, especially in the context of inter-NICU variability in rates of IFI.
We found no effect of fluconazole prophylaxis on mortality rates, in contrast to the systematic review by McGuire et al 14 and the study by Healy et al. 28 This may be explained by 2 factors. First, because most deaths in the study by Kicklighter et al 23 were observed among patients who did not have IFI, direct causality of fluconazole prophylaxis in any trend of mortality rates is questionable; therefore, any effect of fluconazole on mortality rates in the review by McGuire et al, 14 although statistically significant, must be considered with caution. Second, the mortality rate among ELBW infants with IFI was low (14%) in our study, compared with previous reports (37-40%), 4 presumably because of predominance (60%) of C parapsilosis in our study. The neonatal mortality rate resulting from invasive infections with C parapsilosis was one half that for C albicans (9 of 42 patients, 21%; vs 27 of 63 patients, 43%), 30, 31 which reflects its low virulence. 32 The 2 strains are equally sensitive to fluconazole. 30 In contrast, in the study by Kaufman et al, 24 C parapsilosis accounted for only 44.6% of the strains in the placebo group. Another putative factor could be a difference in the use of empiric amphotericin therapy between the study by Kaufman et al 24 and our study. The report on empiric amphotericin therapy was published by Benjamin et al 21 in 2003, ie, after the initiation of the randomized trial by Kaufman et al 24 and after completion of our control epoch. Nevertheless, in our study, use of amphotericin B among VLBW infants decreased, rather than increased, during the fluconazole epoch. Finally, systematic reviews of fluconazole prophylaxis for a large number of patients with cancer and patients with solid-organ transplants showed reductions in IFI rates but no effect on mortality rates. 12, 13 Our study has several limitations. The first is that this is a small, single-site, retrospective study with historical controls. The standard method to assess whether fluconazole prophylaxis meets all of the criteria for prophylactic antimicrobial therapy 26 is a multicenter, double-blind, randomized, controlled trial. The reason why we selected a before/after design for our study is described above; the high rate of IFI in our NICU led to a quality improvement decision to start fluconazole prophylaxis, and this study is an analysis of the efficacy and toxicity of this intervention. We selected a compromise between the desire to reduce IFI rates and the fear of toxicity with use of a 4-to 6-week course for all infants. In this retrospective study, to control for possible bias and confounding variables, we conducted a logistic regression analysis with all published significant factors for IFI. We realized that, with such a design, it was possible that ongoing attempts at limiting nosocomial infections might have reduced the rates of all infections, not only IFI. Therefore, we compared changes in rates of bacterial infections and IFI from the control epoch to the fluconazole epoch. There was a statistically significant, although small, difference in CRIB scores, numbers of episodes of bacterial sepsis and of clinical sepsis, and duration of antibiotic therapy between the first and second epochs. We found that fluconazole prophylaxis was associated with halving of the rate of bacterial infections and a sixfold reduction in the rate of IFI. Furthermore, the number of bacterial infections was not an independent factor for IFI in multivariate analysis in our study. The second limitation of our study is the lack of control for fungal colonization. Fungal colonization was reported as a significant factor for IFI in most 24 but not all 1, 4, 33 studies. Another limitation of our study is the lack of certitude about the absence of adverse effects such as toxicity, medication interference, and emergence of resistant organisms, because of the small sample size, retrospective design, and lack of assessment of fungal colonization. Among 562 children (from 12 clinical studies), 34 58 (10.3%) reported 80 treatment-related adverse effects, affecting the gastrointestinal tract (7.7%), skin (1.2%), or liver/biliary system (0.5%); 18 patients (3.2%) discontinued treatment because of primarily gastrointestinal tract symptoms, and 2% to 5% had transiently elevated liver enzyme levels. Fluconazole inhibits 2 cytochrome P-450 reactions, ie, CYP3A4 and CYP2C9, thereby potentially reducing the metabolism of many medications. 35, 36 In our study, MIC data were available for only 3 strains, none of which showed an unusual sensitivity pattern. We searched the literature for randomized trials reporting the rate of resistance associated with fluconazole prophylaxis in other age groups. Our meta-analysis showed a control event rate among patients with cancer or HIV infection of 15.5% (36 of 233 patients) and suggested that prolonged fluconazole administration [37] [38] [39] might increase the risk of resistance to 24.1% (47 of 195 patients), with a RR of 2.03 (95% CI: 1.40 -2.95); however, the sample size yielded a power of only 65%. In a population-based study, only 1.2% of C albicans (the most frequent fungus infecting neonates) isolates were resistant to fluconazole (MIC of Ͼ64 g/mL), compared with 7% of Candida glabrata isolates and 6% of Candida tropicalis isolates. 40 The sample size in the systematic review by McGuire et al 14 (total N ϭ 214) was quite insufficient for detection of a doubling of resistance; the power was only 9%, even if a baseline resistance rate of 1% was assumed. Importantly, at the Karolinska Institute, resistance of C parapsilosis emerged after 12 years of fluconazole use (1990 -2001) , after ϳ1200 VLBW infants were exposed to fluconazole. 41 The experience at the Karolinska Institute had 3 phases, ie, a long period with lack of resistance and low MIC for several years, a 2-year period with appearance of fungi with intermediate MIC (16 -32 g/mL), and a third period with complete resistance. In contrast, resistance may occur after prophylaxis as short as 2 weeks. 42 Triazole resistance may develop in a stepwise manner 41, 43 and may result through Ն1 of the following mechanisms, ie, (1) a relative increase in Candida species with intrinsic resistance, (2) mutations in the gene encoding the azole target, lanosterol demethylase (ERG11), or increased expression of ERG11 and genes encoding multidrug efflux pumps, thereby lowering intracellular drug levels, or (3) differential expression of essential genes (eg, ERG10P) involved in ergosterol synthesis. [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] Our retrospective study suggests that targeted shortcourse fluconazole prophylaxis (only during periods of antibiotic therapy of Ͼ3 days and limited to VLBW infants) might be as efficacious as a 4-to 6-week course in reducing the risk of IFI but would expose fewer infants to a shorter fluconazole course (except for those at highest risk for IFI) and might be cost-effective. Our initial protocol included all infants with BW of Ͻ1500 g or GA of Ͻ32 weeks. Detailed analysis of risk factors for IFI in our own unit allowed us to restrict fluconazole administration to infants with a GA of Ͻ29 weeks in January 2005. In our study, the estimated effective NNT value for ELBW infants was 8, and cost analysis results were favorable to prophylaxis. However, risk factors for IFI seemed to vary greatly among centers. For instance, in the studies by Kaufman et al, 24, 27 entry criteria for prophylaxis included not only a BW of Ͻ1 kg but also central catheter insertion or intubation. In contrast, Feja et al 6 reported recently that, among 45 infants with IFI, 3 had a BW of Ͻ1000 g but did not have central catheters or intubation and 23 had a BW of Ͼ1 kg but had other risk factors, such as gastrointestinal pathologic conditions or previous bacterial sepsis.
Despite several studies showing efficacy of fluconazole prophylaxis for VLBW or ELBW infants, one major question to resolve is whether generalizing fluconazole prophylaxis may eventually enhance development of fungi resistant to azoles, as observed in some adult populations and in the NICU of the Karolinska Institute. 41 In Denmark, including intrinsically resistant fungi, decreased susceptibility to fluconazole and/or itraconazole was detected in 32% of current bloodstream fungal isolates. 54 Current data support the initiation of a multicenter trial 55 to assess the efficacy, cost, toxicity, and potential risks of targeted fluconazole prophylaxis (including the risk of development of fluconazole resistance only after exposure of large numbers of patients) 41 and neurodevelopmental follow-up results. The intervention should be targeted only to infants at high risk for IFI, on the basis of multivariate analysis in the network of participating institutions, and should involve random assignment to either targeted fluconazole prophylaxis or placebo. With the use of this targeted approach, units within a neonatal network with lower rates of bacterial infections or NEC would be expected to use less antibiotic therapy and thus to expose fewer infants to fluconazole and for shorter periods, thereby minimizing costs and risk for developing resistance to azoles.
Only limited pharmacokinetic data are available for the most immature ELBW infants. 26, [56] [57] [58] In adults, fluconazole is excreted mostly unchanged in the urine, with only 11% as inactive metabolites, including a glucuronide and a fluconazole N-oxide. Fluconazole is a substrate for CYP3A4, which is regulated developmentally. 59 Therefore, a multicenter trial should be preceded by or merged with a pharmacokinetic study to determine the appropriate dose and interval of administration at various levels of maturation of renal and liver function.
After this study was completed, 66 infants with GA of Ͻ32 weeks or BW of Ͻ1500 g, including 25 ELBW infants, were born at Weiler Hospital between January 
